GLIVEC in Croatian translation

• glivec
• gliveca

Examples of using Glivec in English and their translations into Croatian

The experience with Glivec in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited see section 5.1.
Iskustvo s Glivecom u bolesnika s MDS/MPD-om povezanim s preraspodjelom gena za PDGFR je vrlo ograničeno vidjeti dio 5.1.

treatment with Glivec was continued until disease progression.
liječenje Glivecom nastavljeno je sve do progresije bolesti.

repeat step 1 and resume Glivec at reduced dose of 300 mg.
trombociti 75 x 109/l. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 300 mg.

This phase III study in adult patients compared treatment with either single-agent Glivec or a combination of interferon-alpha(IFN)
u ovom ispitivanju faze III. u odraslih bolesnika uspoređivalo se liječenje ili samo s jednim agensom- Glivecom ili s kombinacijom interferona-alfa(IFN)

is still unrelated to leukaemia, stop Glivec until ANC 1 x 109/l and platelets.
još uvijek nije povezana s leukemijom, prekinuti primjenu Gliveca sve dok ABN ne bude.

In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of Glivec daily.
U tom kliničkom ispitivanju, 14 bolesnika s HES/KEL-om je liječeno Glivecom od 100 mg do 1000 mg na dan.

Overall, in patients receiving first-line Glivec, the average daily dose delivered was 406± 76 mg.
Ukupno gledajući, prosječna vrijednost dnevne doze dane bolesnicima koji su primali prvu liniju liječenja Glivecom iznosila je 406 ± 76 mg.

molecular response had a clear effect on long-term outcomes in patients on Glivec.
molekularnog odgovora imao je jasan učinak na dugotrajne ishode u bolesnika na Glivecu.

was present in nearly all responders to Glivec treatment.
je bila prisutna kod gotovo svih bolesnika koji su odgovorili na liječenje Glivecom.

This study included 7 patients with MDS/MPD who were treated with Glivec 400 mg daily.
Ovo je kliničko ispitivanje uključivalo 7 bolesnika s MDS/MPD-om koji su liječeni Glivecom 400 mg na dan.

Glivec is indicated for the treatment of adult patients with Kit(CD 117)
Glivec je indiciran za liječenje odraslih bolesnika s Kit( CD 117)

The effect of Glivec treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported Glivec data with the primary data from another Phase III study using IFN+Ara-C(n=325)
Učinak liječenja Glivecom na preživljenje u kroničnoj fazi novodijagnosticiranog KML-a je dodatno ispitivan u retrospektivnoj analizi gore navedenih Glivec podataka uz primarne podatke iz drugog ispitivanja faze III u kojem je primjenjivan INF+Ara-C(n=325)

months of Glivec treatment significantly prolonged overall survival(OS) compared to 12 months of Glivec treatment(HR 0.45[0.22,
mjeseci liječenja Glivecom značajno je produljilo ukupno preživljenje(OS) u usporedbi s 12 mjeseci liječenja Glivecom(omjer rizika 0,

One open label, multicentre, phase II clinical trial(study B2225) was conducted testing Glivec in diverse populations of patients suffering from life-threatening diseases associated with Abl,
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II(studija B2225) za ispitivanje Gliveca u raznim populacijama bolesnika koji pate od bolesti opasnih po život povezanih s Abl,

Thirty-six(36) months of Glivec treatment significantly prolonged RFS compared to 12 months of Glivec treatment(with overall Hazard Ratio(HR)
Trideset i šest(36) mjeseci liječenja Glivecom značajno je produljilo preživljenje bez recidiva bolesti u usporedbi s 12 mjeseci liječenja Glivecom(uz ukupan omjer rizika 0,

47(8.5%) Glivec patients and 63(19.4%) IFN+Ara-C patients had died.
bolesnika na Glivecu i 63(19,4%) bolesnika na INF+Ara-C-u.

Treatment schedule: On the basis of the existing data, Glivec has been shown to be effective
Plan liječenja: na temelju postojećih podataka, Glivec se pokazao učinkovitim i sigurnim u dozi

Glivec was administered intermittently in cohorts 1-5,
Glivec je povremeno primjenjivan u kohortama 1-5,

who received standard chemotherapy without Glivec 69.6% vs.
koji su primali standardnu kemoterapiju bez Gliveca 69,6% u odnosu na 31, 6.

How to store glivec.
Kako čuvati Glivec.